Erlotinib hydrochloride

Jonathan Dowell; John D. Minna; Peter Kirkpatrick

doi:10.1038/nrd1612

Erlotinib hydrochloride

Jonathan Dowell, John D. Minna, Peter Kirkpatrick

Research output: Contribution to journal › Comment/debate › peer-review

158 Scopus citations

Abstract

Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

Original language	English (US)
Pages (from-to)	13-14
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	4
Issue number	1
DOIs	https://doi.org/10.1038/nrd1612
State	Published - Jan 2005

ASJC Scopus subject areas

Pharmacology
Drug Discovery

Access to Document

10.1038/nrd1612

Cite this

@article{f02711d8c790485593d4b4a79c1c1c93,

title = "Erlotinib hydrochloride",

abstract = "Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.",

author = "Jonathan Dowell and Minna, {John D.} and Peter Kirkpatrick",

year = "2005",

month = jan,

doi = "10.1038/nrd1612",

language = "English (US)",

volume = "4",

pages = "13--14",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Erlotinib hydrochloride

AU - Dowell, Jonathan

AU - Minna, John D.

AU - Kirkpatrick, Peter

PY - 2005/1

Y1 - 2005/1

N2 - Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

AB - Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=12144250589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144250589&partnerID=8YFLogxK

U2 - 10.1038/nrd1612

DO - 10.1038/nrd1612

M3 - Comment/debate

C2 - 15962526

AN - SCOPUS:12144250589

SN - 1474-1776

VL - 4

SP - 13

EP - 14

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 1

ER -

Erlotinib hydrochloride

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this